Skip to main content

ADVERTISEMENT

breast cancer

05/04/2016
JCP Editors
Accelerated partial breast irradiation (APBI) leads to the same rates of survival and toxicity as whole breast irradiation (WBI) while also producing significantly better cosmetic results, according to phase 3 trial...
Accelerated partial breast irradiation (APBI) leads to the same rates of survival and toxicity as whole breast irradiation (WBI) while also producing significantly better cosmetic results, according to phase 3 trial...
...
05/04/2016
Journal of Clinical Pathways
05/03/2016
JCP Editors
Women younger than 45 years who opt for breast conserving therapy (BCT) over mastectomy may have a higher risk of developing a local recurrence over a 20-year period, according to research presented at European...
Women younger than 45 years who opt for breast conserving therapy (BCT) over mastectomy may have a higher risk of developing a local recurrence over a 20-year period, according to research presented at European...
Women...
05/03/2016
Journal of Clinical Pathways
Research in Review
04/29/2016
JCP Editors
Results from a phase 2 clinical trial showed that combination neratinib and paclitaxel treatment better managed central nervous system progression versus trastuzumab and paclitaxel in patients with ERBB2-positive...
Results from a phase 2 clinical trial showed that combination neratinib and paclitaxel treatment better managed central nervous system progression versus trastuzumab and paclitaxel in patients with ERBB2-positive...
...
04/29/2016
Journal of Clinical Pathways
04/25/2016
JCP Editors
Results from a clinical trial presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA) identified two genetic biomarkers capable of predicting which patients with...
Results from a clinical trial presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA) identified two genetic biomarkers capable of predicting which patients with...
...
04/25/2016
Journal of Clinical Pathways
Research in Review
04/11/2016
JCP Editors
Human epidermal growth factor receptor-2 (HER-2) expression may be a key indicator of recurrence risk in patients with breast cancer, though PIK3CA mutations have no prognostic value, according to a recent...
Human epidermal growth factor receptor-2 (HER-2) expression may be a key indicator of recurrence risk in patients with breast cancer, though PIK3CA mutations have no prognostic value, according to a recent...
Human...
04/11/2016
Journal of Clinical Pathways
Research in Review
04/08/2016
JCP Editors
A study conducted by members of the American College of Surgeons has identified a need for greater uniformity and guidelines regarding radiation therapy following neoadjuvant chemotherapy in patients with initial...
A study conducted by members of the American College of Surgeons has identified a need for greater uniformity and guidelines regarding radiation therapy following neoadjuvant chemotherapy in patients with initial...
A...
04/08/2016
Journal of Clinical Pathways
Research in Review
03/22/2016
JCP Editors
Researchers at the University of Texas MD Anderson Cancer Center (Houston, TX) have developed a novel staging system that incorporates tumor biology as a critical prognostic indicator for women with breast cancer who...
Researchers at the University of Texas MD Anderson Cancer Center (Houston, TX) have developed a novel staging system that incorporates tumor biology as a critical prognostic indicator for women with breast cancer who...
...
03/22/2016
Journal of Clinical Pathways
03/08/2016
JCP Editors
Norah Lynn Henry, MD, University of Michigan (Ann Arbor, MI), presented findings to suggest that newly diagnosed patients with early-stage breast cancer often undergo advanced imaging tests despite national...
Norah Lynn Henry, MD, University of Michigan (Ann Arbor, MI), presented findings to suggest that newly diagnosed patients with early-stage breast cancer often undergo advanced imaging tests despite national...
Norah...
03/08/2016
Journal of Clinical Pathways
Clinical Insights
03/08/2016

Andrew C. Gordon, BA; Riad Salem, MD, MBA; Robert J. Lewandowski, MD

From the Division of Interventional Oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 

Andrew C. Gordon, BA; Riad Salem, MD,...
Breast cancer is the most common cancer in women and the second most frequent cause of cancer deaths in women after lung cancer in developed nations.1 Half of patients with metastatic breast cancer (MBC) will be diagnosed with liver...
Breast cancer is the most common cancer in women and the second most frequent cause of cancer deaths in women after lung cancer in developed nations.1 Half of patients with metastatic breast cancer (MBC) will be diagnosed with liver...
Breast cancer is the most common...
03/08/2016
IO Learning
Research in Review
02/16/2016
JCP Editors
Implementation of clinical pathways for breast, colon, and rectal cancers can help narrow the gap between evidence-based treatment guidelines and clinical practice, according to a new study.  With research on...
Implementation of clinical pathways for breast, colon, and rectal cancers can help narrow the gap between evidence-based treatment guidelines and clinical practice, according to a new study.  With research on...
...
02/16/2016
Journal of Clinical Pathways